FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
RBC Capital analyst Luca Issi raised the price target on Moderna (NASDAQ: MRNA) to $160.00 (from $135.00) while maintaining a Outperform rating.
The analyst comments "Despite PDUFA date pushed out by a few weeks, MRNA gets approved for RSV. Vaccine efficacy reported on the label (79%)... More


